source
- Bausch + Lomb appoints board chair Thomas Appio as interim CEO after Brent Saunders departsBausch + Lomb announced that board chair Thomas Appio will serve as interim chief executive, taking over immediately from Brent Saunders, who is leaving the role. Appio, who has held several leade…
- AstraZeneca attributes Phase 3 failure of bone disease enzyme therapy to trial design flawsAstraZeneca disclosed that its Phase 3 study of an enzyme replacement therapy for a rare genetic bone disorder did not meet its primary objectives. The company said the shortfall was largely due t…